NCT07444762已完成3 期
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Versus Monotherapy of DW5421A in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- LDL-C change rate
研究概览
简要总结
This is a multicenter, randomized, double-blind, active-controlled, parallel, phase III clinical trial to evaluate the efficacy and safety of combination therapy of DW5421A/DW5421B versus monotherapy of DW5421A in patients with primary hypercholesterolemia or mixed dyslipidemia.
详细描述
The primary objective is to demonstrate the superiority of combination therapy of DW5421A/DW5421B over monotherapy of DW5421A by comparing the change in LDL-C at week 8 after administration. Approximately equal numbers of patients were randomized in a 1:1 ratio to receive combination therapy of DW5421A/DW5421B or monotherapy of DW5421A for 8 weeks. Efficacy and safety assessments were conducted at week 4 and week 8.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Subjects must meet all of the following criteria to be eligible for the study: [Screening]
- •Male or female aged ≥19 years
- •Subjects diagnosed with primary hypercholesterolemia or mixed dyslipidemia
- •Subjects who satisfy both of the following criteria at Visit 1: (1) Triglyceride (TG) < 400 mg/dL; (2) Low-density lipoprotein cholesterol (LDL-C) ≤ 250 mg/dL
- •At Visit 1, for subjects who are receiving hypercholesterolemia treatment, those who, in the investigator's judgment, can medically and appropriately discontinue their existing hypercholesterolemia treatment for the duration of the clinical trial.
- •Subjects who voluntarily provided written informed consent to participate in this clinical trial.
- •[Randomization]
- •If currently receiving hypercholesterolemia treatment, subjects who have undergone a washout period of at least 4 weeks prior to Visit
- •Subjects who have implemented TLC for at least 4 weeks prior to Visit 2 and have continued TLC through Visit
- •Subjects whose RIP IP compliance during the run-in period is between 70% and 130%.
- •Subjects whose central laboratory test results at Visit 2 meet the criteria.
排除标准
- •Subjects who meet any of the following conditions will not be eligible to participate in this clinical trial:
- •Presence of any of the following medical histories or past surgical histories:
- •Acute arterial disease-related history (as of Visit 1, within the 12-week period preceding the visit including: Unstable angina, myocardial infarction, transient ischemic attack (TIA), cerebrovascular disease, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI)) Exception: Subjects whose events occurred more than 12 weeks before Visit 1, have been adjudicated as cured, or are in a stable state (ex: managed with a stable drug dosage for at least 12 weeks prior to Visit 1) may be eligible.
- •Hypersensitivity or prior exposure to the investigational product's active ingredients (pitavastatin, ezetimibe) or to any dyslipidemia-treating agents.
- •History of fibromyalgia, myopathy, rhabdomyolysis, or other hereditary myopathies, or a family history of such conditions.
- •Severe heart failure (NYHA functional class III or IV).
- •Any surgical or internal medical condition that could affect the absorption, distribution, metabolism, or excretion of the investigational drug (excluding uncomplicated appendectomy or hernia repair).
- •A history of drug or alcohol abuse within 1 year prior to Visit
- •A history of malignancy (however, the following cases are eligible for participation):
- •① If at least 5 years have passed since completion of treatment for the tumor as of Visit 1, or if the subject is disease-free status.
- •② If at least 3 years have passed as of Visit 1 since complete excision of basal cell carcinoma or squamous cell carcinoma of the skin, curative resection of papillary thyroid carcinoma, or successful treatment of cervical carcinoma in situ.
- •2. Subjects with the following comorbidities:
- •Uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)
- •Uncontrolled diabetes mellitus (HbA1c ≥ 9%)
- •Uncontrolled thyroid dysfunction (TSH ≥ 1.5 × ULN)
- •Hepatic dysfunction (AST or ALT ≥ 2 × ULN)
- •Renal impairment (eGFR < 30 mL/min/1.73 m²)
- •CK ≥ 2 × ULN
- •Biliary obstruction or cholestasis
- •Moderate hepatic disease or active liver disease
- •Hypothyroidism
- •Uncontrolled arrhythmia, as determined by the investigator
- •Interstitial lung disease
- •Subjects who are administrating or are expected to administer concomitant medications prohibited by this clinical trial.
- •4. Subjects with chronic conditions requiring continuous use of systemic corticosteroids or immunosuppressants.
- •5. Subjects with secondary dyslipidemia due to conditions such as Cushing's syndrome, hypothyroidism, obstructive liver disease, or nephrotic syndrome.
- •6. Contraception and pregnancy:
- •Pregnant or breastfeeding women, or those planning to become pregnant or breastfeed during the clinical trial period.
- •Women of childbearing potential and men who do not agree to use appropriate contraception as specified in the protocol during the clinical trial period.
- •7. Subjects who have participated in another clinical trial and administered investigational product (or undergone an investigational medical device procedure) within 12 weeks prior to screening (however, enrollment may be permitted if participation was limited to an observational or retrospective study and, in the investigator's judgment, does not affect the efficacy or safety of this clinical trial).
- •8. Subjects deemed unsuitable for participation in this clinical trial at the investigator's discretion.
研究组 & 干预措施
Combination Therapy of DW5421A/DW5421B
Experimental
Combination Therapy of DW5421A/DW5421B
干预措施: DW5421A (Drug)
Combination Therapy of DW5421A/DW5421B
Experimental
Combination Therapy of DW5421A/DW5421B
干预措施: DW5421B (Drug)
Monotherapy of DW5421A
Active Comparator
Monotherapy of DW5421A
干预措施: DW5421A (Drug)
Monotherapy of DW5421A
Active Comparator
Monotherapy of DW5421A
干预措施: DW5421B Placebo (Drug)
结局指标
主要结局
LDL-C change rate
时间窗: week 8
LDL-C change rate at week 8 compared with baseline
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionOcular HypertensionNCT07335211Huons Co., Ltd.206
尚未招募
3 期
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular LymphomaNCT07355283ImmuneOnco Biopharmaceuticals (Shanghai) Inc.198
招募中
3 期
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational AgeSmall for Gestational AgeNCT07309562Xiamen Amoytop Biotech Co., Ltd.141
已完成
3 期
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 DiabetesType 1 DiabetesNCT07282054Tonghua Dongbao Pharmaceutical Co.,Ltd550
招募中
2 期
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsAllergic AsthmaNCT07342803Longbio Pharma200